Header Logo

Connection

Leslie Shaw to Tacrolimus

This is a "connection" page, showing publications Leslie Shaw has written about Tacrolimus.
Connection Strength

1.662
  1. Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation. 2010 Jul 15; 90(1):31-7.
    View in: PubMed
    Score: 0.342
  2. McKaig SJ, Kelly D, Shaw L. Investigation of the effect of FK506 (tacrolimus) and cyclosporin on gingival overgrowth following paediatric liver transplantation. Int J Paediatr Dent. 2002 Nov; 12(6):398-403.
    View in: PubMed
    Score: 0.201
  3. Sindhi R, Webber S, Goyal R, Reyes J, Venkataramanan R, Shaw L. Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. Transplant Proc. 2002 Aug; 34(5):1960.
    View in: PubMed
    Score: 0.197
  4. Oellerich M, Armstrong VW, Sch?tz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem. 1998 Jul; 31(5):309-16.
    View in: PubMed
    Score: 0.149
  5. Shaw LM, Brayman KL. FK-506 therapeutic drug monitoring. Clin Chem. 1994 Dec; 40(12):2207-8.
    View in: PubMed
    Score: 0.116
  6. Yatscoff RW, Shaw LM. Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. Ther Drug Monit. 1992 Aug; 14(4):267-8.
    View in: PubMed
    Score: 0.099
  7. Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008 Mar 27; 85(6):821-6.
    View in: PubMed
    Score: 0.073
  8. Schubert M, Venkataramanan R, Holt DW, Shaw LM, McGhee W, Reyes J, Webber S, Sindhi R. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant. 2004 May; 4(5):767-73.
    View in: PubMed
    Score: 0.056
  9. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, Scheller D, Ersfeld D, Frick M, Fitzsimmons WE, Virji M, Jain A, Brayman KL, Shaked A. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001 May; 41(5):542-51.
    View in: PubMed
    Score: 0.045
  10. MacFarlane GD, Shaw LM, Venkataramanan R, Mullins R, Scheller DG, Ersfeld DL. Analysis of whole blood tacrolimus concentrations in liver transplant patients exhibiting impaired liver function. Ther Drug Monit. 1999 Dec; 21(6):585-92.
    View in: PubMed
    Score: 0.041
  11. Shaw LM, Holt DW, Keown P, Venkataramanan R, Yatscoff RW. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther. 1999 Oct; 21(10):1632-52; discussion 1631.
    View in: PubMed
    Score: 0.041
  12. MacFarlane GD, Scheller DG, Ersfeld DL, Shaw LM, Venkatarmanan R, Sarkozi L, Mullins R, Fox BR. Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus (FK506) in whole blood. Clin Chem. 1999 Sep; 45(9):1449-58.
    View in: PubMed
    Score: 0.040
  13. Schulman SL, Shaw LM, Jabs K, Leonard MB, Brayman KL. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. Transplantation. 1998 May 27; 65(10):1397-8.
    View in: PubMed
    Score: 0.037
  14. Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998 Feb; 44(2):381-7.
    View in: PubMed
    Score: 0.036
  15. Weber M, Deng S, Arenas J, Aradhye S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. Transplant Proc. 1997 Dec; 29(8):3669-70.
    View in: PubMed
    Score: 0.036
  16. Salm P, Taylor PJ, Clark A, Balderson GA, Grygotis A, Norris RL, Lynch SV, Shaw LM, Pond SM. High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants. Ther Drug Monit. 1997 Dec; 19(6):694-700.
    View in: PubMed
    Score: 0.036
  17. Shaw LM. Mycophenolate mofetil: pharmacokinetic strategies for optimizing immunosuppression. Drug Metabol Drug Interact. 1997; 14(1):33-40.
    View in: PubMed
    Score: 0.033
  18. Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem. 1996 Aug; 42(8 Pt 2):1316-21.
    View in: PubMed
    Score: 0.033
  19. de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009 Dec; 36(6):541-64.
    View in: PubMed
    Score: 0.020
  20. Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009 Jul; 9(7):1607-19.
    View in: PubMed
    Score: 0.020
  21. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit. 2002 Feb; 24(1):59-67.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.